These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20065206)

  • 1. Prescribing optimal drug therapy for older people: sending the right message: comment on "impact of FDA black box advisory on antipsychotic medication use".
    Rochon PA; Anderson GM
    Arch Intern Med; 2010 Jan; 170(1):103-6. PubMed ID: 20065206
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA drug prescribing warnings: is the black box half empty or half full?
    Wagner AK; Chan KA; Dashevsky I; Raebel MA; Andrade SE; Lafata JE; Davis RL; Gurwitz JH; Soumerai SB; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):369-86. PubMed ID: 16294363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
    Olfson M; Marcus SC; Druss BG
    Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label medication use in adult critical care patients.
    Lat I; Micek S; Janzen J; Cohen H; Olsen K; Haas C
    J Crit Care; 2011 Feb; 26(1):89-94. PubMed ID: 20716478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive outcomes through the appropriate use of off-label prescribing.
    Bright JL
    Arch Intern Med; 2006 Dec 11-25; 166(22):2554-5; author reply 2555. PubMed ID: 17159026
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of FDA black box advisory on antipsychotic medication use.
    Dorsey ER; Rabbani A; Gallagher SA; Conti RM; Alexander GC
    Arch Intern Med; 2010 Jan; 170(1):96-103. PubMed ID: 20065205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thinking outside the (black) box: a new research agenda.
    Seligman PJ
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):387-9. PubMed ID: 16739245
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of the Food and Drug Administration's antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings.
    Desai VC; Heaton PC; Kelton CM
    Alzheimers Dement; 2012 Sep; 8(5):453-7. PubMed ID: 22285636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.
    Nemeroff CB; Kalali A; Keller MB; Charney DS; Lenderts SE; Cascade EF; Stephenson H; Schatzberg AF
    Arch Gen Psychiatry; 2007 Apr; 64(4):466-72. PubMed ID: 17404123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescriber compliance with black box warnings in older adult patients.
    Ricci JR; Coulen C; Berger JE; Moore MC; McQueen A; Jan SA
    Am J Manag Care; 2009 Nov; 15(11):e103-8. PubMed ID: 19895180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk management of marketed drugs: FDA and the interface with the practice of medicine.
    Uhl K; Honig P
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):205-8. PubMed ID: 11501332
    [No Abstract]   [Full Text] [Related]  

  • 13. Prescribing antipsychotic medications to people with dementia.
    Croucher M
    N Z Med J; 2011 Apr; 124(1333):68. PubMed ID: 21750587
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcomes of antipsychotic drug use in community-dwelling elders with dementia.
    Kolanowski A; Fick D; Waller JL; Ahern F
    Arch Psychiatr Nurs; 2006 Oct; 20(5):217-25. PubMed ID: 17010825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of FDA Black Box Warning on Psychotropic Drug Use in Noninstitutionalized Elderly Patients Diagnosed With Dementia: A Retrospective Study.
    Singh RR; Nayak R
    J Pharm Pract; 2016 Oct; 29(5):495-502. PubMed ID: 25917167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA "black box" labeling.
    Meyer RJ
    Ann Emerg Med; 2003 Apr; 41(4):559-60. PubMed ID: 12658256
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of implementing alerts about medication black-box warnings in electronic health records.
    Yu DT; Seger DL; Lasser KE; Karson AS; Fiskio JM; Seger AC; Bates DW
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):192-202. PubMed ID: 21254291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic prescribing to older people living in care homes and the community in England and Wales.
    Shah SM; Carey IM; Harris T; Dewilde S; Cook DG
    Int J Geriatr Psychiatry; 2011 Apr; 26(4):423-34. PubMed ID: 20878663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label prescribing of medications for pain: maintaining optimal care at an intersection of law, public policy, and ethics.
    Ruble J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):146-52. PubMed ID: 22764854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.